Significance of measurement of serum trough level and anti‐drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the <scp>DIAMOND</scp> trial

Abstract

Adalimumab trough levels and AAA occurrence were significantly associated with clinical remission. Higher 6TGN affected AAA negativity. The combination therapy is beneficial in some relevant aspects for CD patients. (UMIN Registration No. 000005146).